Publications by authors named "Denise Trone"

Claim this Profile
R
Repotrectinib in Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, D Ross Camidge, Jessica J Lin, Sang-We Kim, Benjamin J Solomon, Denise Trone

N Engl J Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Food on the Pharmacokinetics of Quizartinib.
Jianke Li, Melissa Holmes, Martin Kankam, Denise Trone, Jeanne Mendell

Clin Pharmacol Drug Dev· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A drug-drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics.
Jianke Li, Denise Trone, Jeanne Mendell, Patrick O'Donnell, Natalie Cook

Cancer Chemother Pharmacol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Jianke Li, Martin Kankam, Denise Trone, Guy Gammon

Br J Clin Pharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
Alexander Drilon, Siqing Fu, Manish R Patel, Marwan Fakih, Ding Wang, Denise Trone

Cancer Discov· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML.
Jorge E Cortes, Martin S Tallman, Gary J Schiller, Denise Trone, Guy Gammon

Blood· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Kyriakos P Papadopoulos, Eytan Ben-Ami, Amita Patnaik, Denise Trone, Jianke Li

BMC Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Jorge Cortes, Alexander E Perl, Hartmut Döhner, Hagop Kantarjian, Giovanni Martinelli, Denise Trone

Lancet Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.
Brenda M Sandmaier, Samer Khaled, Betül Oran, Guy Gammon, Denise Trone

Am J Hematol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Jessica K Altman, James M Foran, Keith W Pratz, Denise Trone, Jorge E Cortes

Am J Hematol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
Farrukh T Awan, Peter Hillmen, Andrzej Hellmann, Tadeusz Robak, Steven G Hughes, Denise Trone

Br J Haematol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
Jorge E Cortes, Hagop Kantarjian, James M Foran, Darejan Ghirdaladze, Mamia Zodelava, Denise Trone

J Clin Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis